Skip to main content
SpringerLink
Log in

Symptom Management in Gastrointestinal Cancers

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

Abstract

Symptom management for gastrointestinal (GI) cancers depends on the type of cancer, the stage, the presence and kind of systemic symptoms such as anorexia, early satiety nausea, dysgeusia and smell changes, and comorbidities. Symptoms occur early, particularly in esophageal, gastric, and pancreatic cancers. Clinicians should assess a patient’s symptom burden at the time of diagnosis using validated questionnaires. Symptoms appear to cluster rather than appear in a random fashion. A group of symptoms may help in cancer diagnosis, management, and prognostication. Certain symptom clusters negatively affect quality of life and influence treatment compliance of patients as well as add to caregiver burden. Assessing evolving symptoms with follow-up and early palliative intervention can improve quality of life for a cancer patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cancer Facts & Figures 2018. Atlanta: American Cancer Society. 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed 12 June 2018.

  2. Hui D, Shamieh O, Paiva CE, Perex-Cruz PE, Kwon JH, Muckaden MA, et al. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicenter study. Cancer. 2015;121(17):3027–35.

    Article  PubMed  Google Scholar 

  3. Kirkova J, Walsh D, Aktas A, Davis MP. Cancer symptom clusters: old concept but new data. Am J Hosp Palliat Care. 2010;27(4):282–8.

    Article  PubMed  Google Scholar 

  4. Aktas A. Cancer symptom clusters: current concepts and controversies. Curr Opin Support Palliat Care. 2013;7(1):38–44.

    Article  PubMed  Google Scholar 

  5. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

    Article  CAS  PubMed  Google Scholar 

  6. Garla P, Waitzberg DL, Tesser A. Nutritional therapy in gastrointestinal cancers. Gastroenterol Clin N Am. 2018;47(1):231–42.

    Article  Google Scholar 

  7. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.

    Article  PubMed  Google Scholar 

  8. Strasser F, Bruera ED. Up to date on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16(3):589–617.

    Article  PubMed  Google Scholar 

  9. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.

    Article  PubMed  Google Scholar 

  10. Strasser F, Bruera E. Cancer anorexia/cachexia syndrome: epidemiology, pathogenesis, and assessment. In: Ripamonti C, Bruera E, editors. Gastrointestinal symptoms in advanced cancer patients. New York: Oxford University Press; 2002.

    Google Scholar 

  11. Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17–29.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–7.

    Article  CAS  PubMed  Google Scholar 

  13. Warren S. The immediate cause of death in cancer. Am J Med Sci. 1932;184:610–3.

    Article  Google Scholar 

  14. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand S. Appetite and cancer associated anorexia: a review. J Clin Oncol. 2004;22(8):1510–7.

    Article  CAS  PubMed  Google Scholar 

  15. Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of anorexia. Support Care Cancer. 2009;17(12):1531–41.

    Article  PubMed  Google Scholar 

  16. Kirkova J, Davis MP, Walsh D, Tiernen E, O’leary N, LeGrand SB, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24(9):1459–73.

    Article  PubMed  Google Scholar 

  17. Davis MP, Yavuzsen T, Kirkova J, Walsh D, Karafa M, LeGrand S, et al. Validation of a simplified anorexia questionnaire. J Pain Symptom Manag. 2009;38(5):691–7.

    Article  Google Scholar 

  18. Andreyev HJ, Norman AR, Oates J, Cunnigham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34(4):503–9.

    Article  CAS  PubMed  Google Scholar 

  19. Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol. 2014;25(8):1492–9.

    Article  CAS  PubMed  Google Scholar 

  20. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to QOL, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21(6):1569–77.

    Article  PubMed  Google Scholar 

  21. Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol. 2012;84(1):130–48.

    Article  PubMed  Google Scholar 

  22. Mei KL, Batsis JA, Mills JB, Holubar SD. Sarcopenia and sarcopenic obesity: do they predict inferior oncologic outcomes after gastrointestinal cancer surgery? Perioper Med (Lond). 2016;5:30.

    Article  Google Scholar 

  23. Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr. 2016;35(3):724–30.

    Article  CAS  PubMed  Google Scholar 

  24. Chow R, Bruera E, Chiu L, Chow S, Chiu N, Lam H, et al. Enteral and parenteral nutrition in cancer patients: a systematic review and meta-analysis. Ann Palliat Med. 2016;5(1):30–41.

    PubMed  Google Scholar 

  25. Stephenson J, Davies A. An assessment of etiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14:348–53.

    Article  PubMed  Google Scholar 

  26. Wickham R. Evolving treatment paradigms for chemotherapy-induced nausea and vomiting. Cancer Control. 2012;19(2 Suppl):3–9.

    Article  PubMed  Google Scholar 

  27. Darmani NA, Crim JL, Janoyan JJ, Abad J, Ramirez J. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 2009;1248:40–58.

    Article  CAS  PubMed  Google Scholar 

  28. Gordon P, Le Grand SB, Walsh D. Nausea and vomiting in advanced cancer. Eur J Pharmacol. 2014;722:187–91.

    Article  CAS  PubMed  Google Scholar 

  29. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer related pain: a call for the use of standardized outcome measures. J Pain. 2015;16(10):935–46.

    Article  PubMed  Google Scholar 

  30. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, et al. Malignant gastroparesis: pathogenesis and management of an under recognized disorder. J Support Oncol. 2007;5(8):355–63.

    CAS  PubMed  Google Scholar 

  31. Davis MP, Walsh D, Lagman R, Yavuzsen T. Early satiety in cancer patients: a common and important but under recognized symptom. Support Care Cancer. 2006;14(7):693–8.

    Article  PubMed  Google Scholar 

  32. Warr DG. Chemotherapy and cancer related nausea and vomiting. Curr Oncol. 2008;15(Suppl 1):4–9.

    Article  Google Scholar 

  33. Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: a critical update. World J Gastroenterol. 2015;21(41):11793–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Poon M, Hwang J, Dennis K, DeAngelis C, Zhang L, Chung H, et al. A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy. Support Care Cancer. 2016;24(4):1545–61.

    Article  PubMed  Google Scholar 

  35. Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, et al. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol. 2012;19(6):e414–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med. 1983;309(13):796.

    Article  CAS  PubMed  Google Scholar 

  37. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 1991;2(2):107–14.

    Article  CAS  PubMed  Google Scholar 

  38. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1987;5(1):141–9.

    Article  CAS  PubMed  Google Scholar 

  39. Kris MG, Urba SG, Schwartzberg LS. Clinical round table monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clin Adv Hematol Oncol. 2011;9(1):supp1–15.

    Google Scholar 

  40. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–94.

    Article  CAS  PubMed  Google Scholar 

  41. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–an update. Support Care Cancer. 2005;13(2):80–4.

    Article  PubMed  Google Scholar 

  42. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006;4(2 Suppl 1):3–8.

    CAS  PubMed  Google Scholar 

  43. Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2012;20(5):1043–7.

    Article  PubMed  Google Scholar 

  44. Schwartzberg L. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):825–34.

    Article  PubMed  Google Scholar 

  45. Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104(6):711–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag. 2000;20(2):113–21.

    Article  CAS  Google Scholar 

  47. Hesketh PJ, Bohlke K, Kris MG. Antiemetics: American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract. 2017;13(12):825–30.

    Article  PubMed  Google Scholar 

  48. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer. 1998;6(3):244–7.

    Article  CAS  PubMed  Google Scholar 

  49. Morrow GR, Roscoe JA, Hickok JT. Nausea and vomiting. In: Holland JC, Breitbart W, Jacobsen PB, et al., editors. Psycho-oncology. New York: Oxford University Press; 1998. p. 476–84.

    Google Scholar 

  50. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995;18(2):170–5.

    Article  CAS  PubMed  Google Scholar 

  51. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 1995;13(2):117–21.

    Article  Google Scholar 

  52. Ravazi D, Delvaux N, Farvacques CJ, De Brier F, Van Heer C, Kaufman L, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double- blind, placebo-controlled study assessing the usefulness of a alprazolam. J Clin Oncol. 1993;11(7):1384–90.

    Article  Google Scholar 

  53. Carey MP, Burish TG. Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull. 1988;104(3):307–25.

    Article  CAS  PubMed  Google Scholar 

  54. Lyles JN, Burish TG, Krozely MG, Oldham RK. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol. 1982;50(4):509–24.

    Article  CAS  PubMed  Google Scholar 

  55. Redd WH, Andresen GV, Minagawa RY. Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol. 1982;50(1):14–9.

    Article  CAS  PubMed  Google Scholar 

  56. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med. 1982;307(24):1476–80.

    Article  CAS  PubMed  Google Scholar 

  57. Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34(4):381–6.

    Article  PubMed  Google Scholar 

  58. Tageja N, Groninger H. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J. 2016;92(1083):33–40.

    Article  CAS  Google Scholar 

  59. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 2008;26(34):5618–29.

    Article  PubMed  Google Scholar 

  60. Miroddi M, Sterrantino C, Simonelli I, Ciminata G, Philips RS, Calapai G. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: a meta-analysis of 18 randomized controlled clinical trials. Crit Rev Oncol Hematol. 2015;96(2):355–61.

    Article  PubMed  Google Scholar 

  61. Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol. 2014;20(14):3751–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14(6):505–15.

    Article  PubMed  Google Scholar 

  63. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterization of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41.

    Article  CAS  PubMed  Google Scholar 

  64. Sonic ST, Elting RS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.

    Google Scholar 

  65. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21(15):2896–903.

    Article  CAS  PubMed  Google Scholar 

  66. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.

    Article  CAS  PubMed  Google Scholar 

  67. Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015;51(11):1026–33.

    Article  CAS  PubMed  Google Scholar 

  68. Grothey A, Georga S, van Cutsem E, Blsy JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19(6):669–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al., The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61.

    Article  PubMed  Google Scholar 

  70. Feldman JM. Carcinoid tumors and syndrome. Semin Oncol. 1987;14(3):237–46.

    CAS  PubMed  Google Scholar 

  71. Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):163–77.

    Article  PubMed  Google Scholar 

  72. Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol. 2018;14(12):1155–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, et al. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasm, focus on systemic therapeutic options: a systematic review. Future Oncol. 2015;11(13):1947–59.

    Article  CAS  PubMed  Google Scholar 

  74. van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15(4):235–49.

    Article  PubMed  Google Scholar 

  75. Doosti-Irani A, Mansournia MA, Rahimi-Foroushani A, Haddad P, Holakouie-Naieni K. Complications of stent placement in patients with esophageal cancer: a systematic and network analysis. PLoS One. 2017;12(10):e0184784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Miller G, Boman J, Shrier I, Gordon PH. Small-bowel obstruction secondary to malignant disease: an 11-year audit. Can J Surg. 2000;43(5):353–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet. 1985;2(8462):990–3.

    Article  CAS  PubMed  Google Scholar 

  78. Librach SL, Horvath AN, Langlois EA. Malignant bowel obstruction. In: Palliative Medicine – a case based manual. 2nd ed. New York: Oxford University Press Inc.; 2005. p. 213–7.

    Google Scholar 

  79. Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manag. 2007;34(Suppl 1):49–59.

    Article  Google Scholar 

  80. Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159–69.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Tuca A, Codorniu N, Garzón, Serrano G. Malignant bowel obstruction due to advanced cancer in palliative care: observational and descriptive study. 5th Research Forum of European Association for Palliative Care; May 2008; Trodheim, Norway. Poster: 462.

    Google Scholar 

  82. Laval G, Marcelin-Benazech B, Guirimand F. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;48(1):75–91.

    Article  Google Scholar 

  83. Francescutti V, Miller A, Satchidanand Y. Management of bowel obstruction in patients with stage IV cancer: predictors of outcome after surgery. Ann Surg Oncol. 2013;20(3):707–14.

    Article  PubMed  Google Scholar 

  84. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223–33.

    Article  CAS  PubMed  Google Scholar 

  85. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol). 2003;15(2):59–72. (review).

    Article  CAS  PubMed  Google Scholar 

  86. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HM. Pathogenesis ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 1993;53:2631–43.

    CAS  PubMed  Google Scholar 

  87. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manag. 1998;16(2):96–101.

    Article  CAS  Google Scholar 

  88. Fleming ND, Alvarez-Secord A, Von Grueningen V, Miller MJ, Abernetjy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag. 2009;38(3):341–9.

    Article  Google Scholar 

  89. Randle RW, Sweet KR, Swords DS, Shen P, Stewart JH, Levine EA, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21(5):1474–9.

    Article  PubMed  Google Scholar 

  90. Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9.

    Article  PubMed  Google Scholar 

  91. Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. World J Gastroenterol. 2014;20(28):9345–53.

    PubMed  PubMed Central  Google Scholar 

  92. Ho CS, Warkentin AE. Evidence based decompression in malignant biliary obstruction. Korean J Radiol. 2012;13(S1):S56–61.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Franc M, Michalski B, Kuczerawy I, Szuta J, Skrzypulec-Plinta V. Cancer related fatigue syndrome in neoplastic diseases. Prz Menopauzalny. 2014;13(6):352–5.

    PubMed  PubMed Central  Google Scholar 

  94. Huang X, Zhang Q, Kang X, Song Y, Zhao W. Factors associated with cancer-related fatigue in breast cancer patients undergoing endocrine therapy in an urban setting: a cross-sectional study. BMC Cancer. 2010;10:453.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Pettersson G, Berterö C, Unosson M, Börjeson S. Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. Support Care Cancer. 2014;22(5):1171–9.

    Article  PubMed  Google Scholar 

  96. Li SX, Liu BB, Lu JH. Longitudinal study of cancer-related fatigue in patients with colorectal cancer. Asian Pac J Cancer Prev. 2014;15(7):3029–33.

    Article  PubMed  Google Scholar 

  97. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Restrictions in QOL in colorectal cancer patients over three years after diagnosis: a population based study. Eur J Cancer. 2006;42(12):1848–57.

    Article  PubMed  Google Scholar 

  98. O’Gorman C, Denieffe S, Gooney M. Literature review: preoperative radiotherapy and rectal cancer impact on acute symptom presentation and QOL. J Clin Nurs. 2013;23(3–4):333–51.

    PubMed  Google Scholar 

  99. Stauder MC, Romero BK, Atherton DG, Deschamps C, Jatoi A, Sloan JA, et al. Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer. 2013;21(2):511–9.

    Article  CAS  PubMed  Google Scholar 

  100. Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, et al. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol. 2007;86(1):37–41.

    Article  PubMed  Google Scholar 

  101. Vardy J, Dhillon HM, Pond GR, Rourke SB, Xu W, Dodd A, et al. Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol. 2014;25(12):2404–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Scott JA, Lasch KE, Barsevick AM, Piault-Louis E. Patient’s experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum. 2011;38(3):E191–203.

    Article  PubMed  Google Scholar 

  103. Lin J-M, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metrics. 2009;7:18.

    Article  Google Scholar 

  104. Brola W, Ziomek M, Czernicki J. Fatigue syndrome chronic neurological disorder. Neurol Neurochir Pol. 2007;41(4):340–9.

    PubMed  Google Scholar 

  105. Minton O, Stone PC. The use of proteomics as a research methodology for studying cancer-related fatigue: a review. Palliat Med. 2010;24(3):310–6.

    Article  PubMed  Google Scholar 

  106. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 1989;25(12):1823–9.

    Article  CAS  PubMed  Google Scholar 

  107. De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, et al. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer. 1998;34(11):1705–9.

    Article  PubMed  Google Scholar 

  108. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manag. 2009;38(5):650–62.

    Article  CAS  Google Scholar 

  109. Bruera E, Yennurajalingam S, Palmer JL, Perez-Cruz PE, Frisbee-Hume S, Allo J, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med. 2009;23:325–31.

    Article  CAS  PubMed  Google Scholar 

  111. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Jensen W, Baumann FT, Stein A, Bloch W, Bokemeyer C, de Wit M, et al. Exercise training in patients with advanced gastrointestinal cancer undergoing palliative chemotherapy: a pilot study. Support Care Cancer. 2014;22(7):1797–806.

    PubMed  Google Scholar 

  113. Pachman DR, Price KA, Carey EC. Nonpharmacologic approach to fatigue in patients with cancer. Cancer. 2014;20(5):313–8.

    Article  Google Scholar 

  114. Maguire D, O’Sullivan GC, Collins JK, Morgan J, Shanahan F. Bone marrow micro-metastases and gastrointestinal cancer detection and significance. Am J Gastroenterol. 2000;95:1644–51.

    Article  CAS  PubMed  Google Scholar 

  115. Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2(3):271–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Varma A, Spier BJ, Pfau PR, Safdar N. A case of newly diagnosed metastatic pancreatic cancer presenting with associated immune thrombocytopenic purpura. Wis Med J. 2009;108(9):459–61.

    Google Scholar 

  117. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci. 2010;55(3):548–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Yachimski PS, Friedman LS. Gastrointestinal bleeding in the elderly. Nat Clin Pract Gastroenterol Hepatol. 2008;5(2):80–93.

    Article  PubMed  Google Scholar 

  119. Pelesof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–54.

    Article  Google Scholar 

  120. Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the Blood Center of Wisconsin. Am J Hematol. 2015;90(5):406–10.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Niu J, Mims MP. Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. J Clin Oncol. 2012;30(31):1705.

    Article  Google Scholar 

  122. Mimica M, Tomic M, Babic E, Karin M, Bevanda M, Alfirevic D, et al. Gastric cancer with bone marrow invasion presenting as severe thrombocytopenia. Turk J Gastroenterol. 2014;25(Suppl 1):229–30.

    PubMed  Google Scholar 

  123. Arslan D, Uysal M, Tatli AM, Gunduz S, Sezgin-Goksu S, Bassorgun CI, Coskun HS, Bozcuk H, Savas B. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. Case Rep Oncol Med. 2014;2014:194636.

    PubMed  PubMed Central  Google Scholar 

  124. Yazdi MF, Hashemian Z, Nazmieh H, Ghadimi H. A report of three cases with thrombotic thrombocytopenic purpura (TTP) secondary to an occult gastric adenocarcinoma. Pak J Med Sci. 2009;25(4):689–92.

    Google Scholar 

  125. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine. 2012;91(4):1–11.

    Article  Google Scholar 

  126. Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program. 2012;2012:626–30.

    PubMed  Google Scholar 

  127. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004;5(11):655–63.

    Article  CAS  PubMed  Google Scholar 

  128. Sheth RA, Niekamp A, Quencer KB, Shamoun F, Knuttinen MG, Naidu S, et al. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther. 2017;7(Suppl):S178–85.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, et al. Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism. Am J Med. 2017;131(4):430–7. pii: S0002-9343(17)31277-9.

    Article  CAS  PubMed  Google Scholar 

  130. Elalamy I, Mahe I, Ageno W, Meyer G. Long term treatment of cancer associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15(5):848–57.

    Article  CAS  PubMed  Google Scholar 

  131. Melosky B. Supportive care treatments for toxicities of anti-egfr and other targeted agents. Curr Oncol. 2012;19(Suppl 1):S59–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. De Loughery TG, Beer TM. Bevacizumab and thrombosis: some answers but questions remain. Cancer. 2015;121(7):975–7.

    Article  CAS  Google Scholar 

  133. Newton HB. Neurological complications of systemic cancer. Am Fam Physician. 1999;59(4):878–86.

    CAS  PubMed  Google Scholar 

  134. Giglio P, Gilbert MR. Neurological complications of cancer and treatment. Curr Oncol Rep. 2010;12(1):50–9.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Sio TT, Paredes M, Uzair C. Neurological manifestation of colonic adenocarcinoma. Rare Tumors. 2012;4(2):e32.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Bano N, Najam R, Mateen A. Neurological adverse effects in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. Chemother Res Pract. 2013;2013:379870.

    PubMed  PubMed Central  Google Scholar 

  137. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.

    Article  CAS  PubMed  Google Scholar 

  138. Klicovac T, Djurdjevic A. Psychological aspects of the cancer patients’ education: thoughts, feelings, behavior and body reaction of patients faced with diagnosis of cancer. J BUON. 2010;15(1):153–6.

    Google Scholar 

  139. Deckx L, van Abbema DL, van den Akker M, van den Broeke C, van Driel M, Bulens P, et al. A cohort study on the evolution of psychosocial problems in older patients with breast or colorectal cancer: comparison with younger cancer patients and older primary care patients without cancer. BMC Geriatr. 2015;15:79.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Detrich J, Prust M, Kaiser J. Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 2015;309:224–32.

    Article  CAS  Google Scholar 

  142. Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med. 2004;18(3):184–94.

    Article  PubMed  Google Scholar 

  143. Merskey H, Bugduk N. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press; 1994.

    Google Scholar 

  144. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49.

    Google Scholar 

  145. Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, LeGrand SB, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14(5):444–53.

    Article  PubMed  Google Scholar 

  146. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.

    Article  CAS  PubMed  Google Scholar 

  147. Pathophysiology of cancer pain and opioid tolerance. In: The British Pain Society’s cancer pain management. 2010. https://www.britishpainsociety.org/static/uploads/resources/files/book_cancer_pain.pdf. Accessed 12 June 2018.

  148. Grond S, Zech D, Difenbach C, Radburgh L, Lehmann KA. Assessment of the cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64(1):107–14.

    Article  CAS  PubMed  Google Scholar 

  149. Walsh D. Pharmacological management of cancer pain. Semin Oncol. 2000;27(1):45–63.

    PubMed  Google Scholar 

  150. Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol Oncol Clin North Am. 2002;16(3):527–41.

    Article  PubMed  Google Scholar 

  151. Stacey B. Management of peripheral neuropathic pain. Am J Phys Med Rehabil. 2005;84(3):S4–S16.

    PubMed  Google Scholar 

  152. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012;153(2):359–65.

    Article  PubMed  Google Scholar 

  153. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with and without, oxaliplatin as first-line treatment in advanced cancer. J Clin Oncol. 2000;18(6):2938–47.

    Article  PubMed  Google Scholar 

  154. Andre T, Boni C, Mounedji-Boudiat L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    Article  CAS  PubMed  Google Scholar 

  155. Briani C, Argyriou A, Izquierd C, Velasco R, Campagnolo M, Alberti P, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19(4):299–306.

    Article  CAS  PubMed  Google Scholar 

  156. Mercandante S, Klepstad P, Kurita GP, Sjogren P, Giarratano A, European Palliative Care Research Collaborative Group (EPCRC). Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96(3):577–83.

    Article  Google Scholar 

  157. Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 1993;4(1):15–21.

    Article  CAS  PubMed  Google Scholar 

  158. Alexandrescu DT, Wiernik PH, Dutcher JP. Chapter 90. Chemotherapy toxicities and complications. In: Young NS, Gerson SL, High KA, editors. Clinical hematology. Philadelphia: Mosby Elsevier; 2006. p. 1144–54.

    Google Scholar 

  159. Kurkjian DC, Ozer H. Management of adverse effects of treatment. In: Devita VT, Lawrence TS, Rosenberg SA, Weinberg RA, editors. DeVita, Hellman and Rosenberg’s cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 2617–38.

    Google Scholar 

  160. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;14(2):333–7.

    Article  CAS  PubMed  Google Scholar 

  161. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–e9.

    Article  CAS  PubMed  Google Scholar 

  162. Lipworth AD, Robert C, Zhu A. Hand-foot syndrome (Hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71.

    Article  CAS  PubMed  Google Scholar 

  163. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Investig New Drugs. 1990;8(1):57–63.

    Article  CAS  Google Scholar 

  164. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824–9.

    Article  CAS  PubMed  Google Scholar 

  165. Curran CF, Luce JK. Fluorouracil and palmar-plantar erythrodysesthesia. Ann Intern Med. 1989;111(10):858.

    Article  CAS  PubMed  Google Scholar 

  166. Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, et al. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res. 1993;13(5c):1781–3.

    CAS  PubMed  Google Scholar 

  167. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the ant epidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–76.

    Article  CAS  PubMed  Google Scholar 

  168. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: dermatology–oncology perspective. Skin Therapy Lett. 2007;12(6):1–5.

    CAS  PubMed  Google Scholar 

  169. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park). 2006;20(5 Suppl 2):26–34.

    Google Scholar 

  170. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.

    Article  CAS  PubMed  Google Scholar 

  171. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390–6.

    Article  CAS  PubMed  Google Scholar 

  172. Scope A, Lieb J, Dusza S, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. J Am Acad Dermatol. 2009;61(4):614–20.

    Article  CAS  PubMed  Google Scholar 

  173. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor–associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10(5):345–56.

    Article  PubMed  Google Scholar 

  174. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16(1):16–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Burris HA, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15(11):1227–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Balcova, Izmir, Turkey

    Tugba Yavuzsen

  2. Department of Medical Oncology, Karadeniz Technical University, Kanuni Training and Education Hospital, Trabzon, Turkey

    Nazli Kazaz

  3. Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Menteşe, Mugla, Turkey

    Özgür Tanriverdi

  4. Department of Medical Oncology, Tepecik Education and Research Hospital, Izmir, Turkey

    Tulay Akman

  5. Lerner School of Medicine, Case Western Reserve University, Palliative Care Department, Geisinger Medical Center, Danville, PA, USA

    Mellar P. Davis

Authors
  1. Tugba Yavuzsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nazli Kazaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Özgür Tanriverdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tulay Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mellar P. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yavuzsen, T., Kazaz, N., Tanriverdi, Ö., Akman, T., Davis, M.P. (2019). Symptom Management in Gastrointestinal Cancers. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_38

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation